Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir /- ribavirin for hepatitis C genotype 1-final results of the REV1TAL study
John Lubel, Simone Strasser, Katherine A Stuart, Gregory Dore, Alexander Thompson, Stephen Pianko, Steven Bollipo, Joanne L Mitchell, Vincenzo Fragomeli, Tracey Jones, Sarah Chivers, Paul Gow, David Iser, Miriam Levy, Edmund Tse, Alessia Gazzola, Wendy Cheng, Saroj Nazareth, Sam Galhenage, Amanda Wade Show all
Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2017
AbbVie provided drug for patients included in the Compassionate Program and provided funding for the research through an unrestricted grant administered by the Gastroenterological Society of Australia. AbbVie was not involved in the data collection related to this publication. Upon study completion, AbbVie was provided a copy of the publication for the purposes of performing an accuracy review and as a part of routine safety monitoring of patients treated with Viekira Pak (Viekirax)/Exviera.